However, while anti-CD20 therapy (such as rituximab) has been used successfully to treat RA [50], it is not clear why CD20 expression was significantly higher in the RAworsened group at the pre-pregnancy stage, when disease activity was similar to that in the RAimproved group. This evidence concerns the gene MS4A1 and rheumatoid arthritis.